Further supporting its role in CVDs, is the fact that various gain-of-function (GOF) mutations of PCSK9 are associated with hypercholesterolaemia and thereby an elevated risk for cardiac events [19,20,21,22,23]. This evidence concerns the gene PCSK9 and Hypercholesterolemia.